© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Sydney Jennings
Articles
COVID-19 Associated with Higher Long-Term Mortality Than Flu or RSV: New Data
February 03, 2025
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
Stool Tests Still Top Choice for CRC Screening: Daily Dose
February 03, 2025
Your daily dose of the clinical news you may have missed.
7 Drugs Approved for Primary Care: Q4 2024
January 31, 2025
An oral antibiotic for drug-resistant UTIs, a long-awaited therapy for congenital adrenal hyperplasia, and more.
Propranolol May Lower Stroke Risk in Women with Migraine, Study Finds
January 31, 2025
Data set to be presented at ISC 2025 shows that the protective effect of propranolol was stronger for ischemic stroke compared to other stroke types.
FDA Approves First Monotherapy Standalone MDD Treatment: Daily Dose
January 31, 2025
Your daily dose of the clinical news you may have missed.
Axsome Therapeutics: FDA Approves Symbravo for Acute Treatment of Migraine
January 30, 2025
A single oral dose of Symbravo provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours.
Investigational RSV Antiviral Treatment Reduces Viral Load in Phase 2 Human Challenge Trial
January 30, 2025
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
Tool Predicts Age at Cognitive Impairment, Dementia Onset: Daily Dose
January 30, 2025
Your daily dose of the clinical news you may have missed.
PTSD Treatment Advancements: Brexpiprazole-Sertraline Offers New Hope in Phase 3 Trial
January 29, 2025
Data showed that brexpiprazole plus sertraline significantly improved PTSD symptoms vs sertraline alone. Lead author, Lori Davis, MD, discusses more.
FDA Grants Breakthrough Device Designation for Alzheimer Disease Blood Test
January 29, 2025
The Access p-Tau217/β-Amyloid 1-42 plasma ratio blood test is designed to help identify patients with amyloid pathology associated with AD.